… ProQR Announces Second Quarter 2022 Operating and Financial … CNS therapeutic areas, which have strong alignment with ProQR’s oligonucleotide delivery approaches. The Company will … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …
… ProQR to Webcast Virtual Analyst Event on November 18 LEIDEN, … & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … webcast link or from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Archived …
… ProQR to Present at Upcoming Scientific and Industry … & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Second Quarter 2021 Operating and Financial … & CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … eye disease,” said Daniel A. de Boer, Founder and CEO of ProQR. “We completed enrollment in the pivotal trial of …
… ProQR Announces Upcoming Investor Conferences in April and … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … will be accessible from the “Investors & Media” section of ProQR’s website under “ Events ”. Archived webcasts will be …
… ProQR Announces Upcoming Investor Conferences in November and … & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Archived …
… ProQR Announces Results for the Third Quarter of 2017 Key … Scott Armstrong and Thaddeus (Ted) Dryja appointed to ProQR’s Scientific Advisory Board (SAB). In vivo proof of … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
… ProQR Announces Third Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We will enter 2021 with the Illuminate trial of …
… ProQR Announces Second Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We have continued to enroll patients in trials for …
… ProQR Announces Results for the Second Quarter of 2015 … fibrosis," said Daniel de Boer, Chief Executive Officer of ProQR. "I am happy and grateful that we have accomplished … study will also assess sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …